And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

Lilly is seeking approval for donanemab in early-stage Alzheimer's, and is hoping to get a speedy FDA green light on the back of amyloid clearance data as a surrogate marker for clinical efficacy ...

Hunan Provincial Key Laboratory of Cytochemistry, School of Chemistry and Pharmaceutical Engineering, Changsha University of Science and Technology, Changsha 410114, PR China Hunan Provincial Key ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage symptoms and delay their onset, including the recently approved next-gen ...

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

Though most amyloid-targeting drugs have failed, two recent therapeutics, lecanemab and donanemab, have shown limited success, but demonstrate significant side-effects and definitely are not cures.

The National Institute for Health and Care Excellence (NICE) has decided to reconsult on draft guidance for Alzheimer’s treatments donanemab and lecanemab, six months after initially rejecting the ...

Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. On Thursday, 6 March, NICE published further draft guidance for public consultation that ...